Facial Lipoatrophy Trial: Immediate Versus Deferred Injections of Poly-L-Lactic Acid for HIV Facial Lipoatrophy
A Multi-Centre, Open-Label, Randomised Study to Assess the Efficacy, Durability and Safety of Immediate Versus Deferred Injections of Poly-L-Lactic Acid for HIV Facial Lipoatrophy (FLASH)
Sponsor: AIDS Council of New South Wales
Terminated
no change in primary endpoint at week 48
Listed as NCT00126308, this PHASE4 trial focuses on HIV Infections and HIV-Associated Lipodystrophy and remains terminated or withdrawn. Sponsored by AIDS Council of New South Wales, it has been updated 6 times since 2005, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Jun 2022 — Jul 2024 [monthly]
Terminated PHASE4
-
Jan 2021 — Jun 2022 [monthly]
Terminated PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE4
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE4
First recorded
Nov 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AIDS Council of New South Wales
- Abbott
- Bristol-Myers Squibb
- Gilead Sciences
- GlaxoSmithKline
- Hoffmann-La Roche
- Kirby Institute
- Merck Sharp & Dohme LLC
- The University of New South Wales
For direct contact, visit the study record on ClinicalTrials.gov .